MX355103B - Composicion para el tratamiento de desordenes inflamatorios e inmunes. - Google Patents

Composicion para el tratamiento de desordenes inflamatorios e inmunes.

Info

Publication number
MX355103B
MX355103B MX2014011922A MX2014011922A MX355103B MX 355103 B MX355103 B MX 355103B MX 2014011922 A MX2014011922 A MX 2014011922A MX 2014011922 A MX2014011922 A MX 2014011922A MX 355103 B MX355103 B MX 355103B
Authority
MX
Mexico
Prior art keywords
inflammatory
treatment
composition
immune disorders
methylsulphonylmethane
Prior art date
Application number
MX2014011922A
Other languages
English (en)
Other versions
MX2014011922A (es
Inventor
Fredrick Turner Paul
Original Assignee
Eaglepharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901301A external-priority patent/AU2012901301A0/en
Application filed by Eaglepharma Pty Ltd filed Critical Eaglepharma Pty Ltd
Publication of MX2014011922A publication Critical patent/MX2014011922A/es
Publication of MX355103B publication Critical patent/MX355103B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere al tratamiento de un desorden inflamatorio o inmune con una composición farmacéutica incluyendo metilsulfonilmetano, glucosamina y glicina o sales farmacéuticamente aceptables o derivados de estos compuestos.
MX2014011922A 2012-04-02 2013-04-02 Composicion para el tratamiento de desordenes inflamatorios e inmunes. MX355103B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012901301A AU2012901301A0 (en) 2012-04-02 Treatment of inflammatory and immune disorders
PCT/GB2013/050865 WO2013150292A1 (en) 2012-04-02 2013-04-02 Composition for the treatment of inflammatory and immune disorders

Publications (2)

Publication Number Publication Date
MX2014011922A MX2014011922A (es) 2015-12-03
MX355103B true MX355103B (es) 2018-04-05

Family

ID=48184233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011922A MX355103B (es) 2012-04-02 2013-04-02 Composicion para el tratamiento de desordenes inflamatorios e inmunes.

Country Status (9)

Country Link
US (1) US9387218B2 (es)
EP (1) EP2836208B1 (es)
JP (1) JP6188784B2 (es)
CN (1) CN104427982B (es)
AU (1) AU2013203825B2 (es)
CA (1) CA2869243C (es)
HK (1) HK1207293A1 (es)
MX (1) MX355103B (es)
WO (1) WO2013150292A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051154A1 (en) * 2016-09-15 2018-03-22 Perscellmed Roth & Partner Compound of zinc salicylate and sulphur combination as a novel treatment for asthma and copd

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514421A (en) * 1979-08-30 1985-04-30 Herschler R J Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
US20030069202A1 (en) * 2000-06-02 2003-04-10 Kern Kenneth Norman Compositions, kits, and methods for promoting defined health benefits
US6902739B2 (en) * 2001-07-23 2005-06-07 Nutracea Methods for treating joint inflammation, pain, and loss of mobility
US6841173B2 (en) * 2002-03-26 2005-01-11 Peter L. Reynolds Compositions and methods directed towards sore muscles and joints
US20060251750A1 (en) * 2002-09-30 2006-11-09 Tabor Aaron T Soy formulations and their use in skin care
JP2005013124A (ja) * 2003-06-27 2005-01-20 Toyo Shinyaku:Kk 美容効果を有する食品組成物
US20060029647A1 (en) * 2004-02-09 2006-02-09 Friesen Kim G Composition and method for use in cartilage affecting conditions
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
US20070020218A1 (en) * 2005-07-21 2007-01-25 Eileen Richardson Composition and method for the treatment of psoriasis
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
CN103249407B (zh) * 2010-10-07 2017-05-17 鹰制药私人有限公司 用于治疗抑郁症和其他非感染性疾病的联合疗法

Also Published As

Publication number Publication date
AU2013203825A1 (en) 2013-10-17
JP2015512439A (ja) 2015-04-27
AU2013203825B2 (en) 2015-12-17
WO2013150292A1 (en) 2013-10-10
MX2014011922A (es) 2015-12-03
JP6188784B2 (ja) 2017-08-30
US20150111850A1 (en) 2015-04-23
EP2836208A1 (en) 2015-02-18
CN104427982A (zh) 2015-03-18
EP2836208B1 (en) 2019-09-25
CA2869243C (en) 2021-03-16
CN104427982B (zh) 2017-05-17
CA2869243A1 (en) 2013-10-10
HK1207293A1 (en) 2016-01-29
US9387218B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
EA033555B1 (ru) Фармацевтические композиции для лечения серповидно-клеточного нарушения
HK1206297A1 (en) Pharmaceutical compositions for combination therapy
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
IN2014DN09434A (es)
EP3038647A4 (en) Combination therapy for the treatment of glioblastoma
EP3082817A4 (en) Compositions for drug administration
TW201144301A (en) Processes for preparing linezolid
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
HRP20190050T1 (hr) Farmaceutski pripravci za kombinacijsku terapiju
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
PT2859896T (pt) Composições farmacêuticas para o tratamento de distúrbios musculares
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
IN2013MU01111A (es)
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
IL250201A0 (en) Administration of erythuran or its salts suitable for pharmaceutical use for the treatment of orthomyxovirus infections
MX366309B (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
IN2014DN03010A (es)
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
MX2014011922A (es) Composicion para el tratamiento de desordenes inflamantorios e inmunes.
IN2013CH04314A (es)
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION

Legal Events

Date Code Title Description
FG Grant or registration